Korea Serb... TipsoBoc (Ivosidenib) Begins Price Negotiation for IDH1‑Mutant Cholangiocarcinoma Reimbursement

Korea Serb...'s IDH1‑mutant cholangiocarcinoma drug TipsoBoc (ivosidenib) has moved into the final step of health‑insurance reimbursement – price negotiation. In July, the drug received a favorable assessment from the Pharmaceutical Benefits Evaluation Committee, confirming its suitability for reimbursement. Following a negotiation order from the Ministry of Health and Welfare, negotiations between the National Health Insurance Service and Korea Serb... began this month. The negotiation targets the indication of “IDH1‑mutant adult patients with locally advanced or metastatic cholangiocarcinoma who have prior treatment experience, as monotherapy.” Passing the committee in July cleared a major hurdle toward inclusion in the health‑insurance benefit list.